Article Summary
April 22, 2021
When Can We Safely Return to Normal A Novel Method for Identifying Safe Levels of NPIs in the Context of COVID-19 Vaccinations
[Pre-print, not peer-reviewed] A transmission model with vaccination parameters calibrated to the state of Colorado suggests that complete relaxation of non-pharmaceutical interventions (NPIs) within the next year when vaccination uptake is ≤70% still risks exceeding hospitalization thresholds. The model also suggests that decisions to relax NPIs should account for regional heterogeneity in transmission and travel,…
Hospital Admissions for Abusive Head Trauma at Children’s Hospitals During COVID-19
A retrospective analysis determined that the rate of abusive head trauma (AHT) had decreased substantially among children during the pandemic. AHT was used as a surrogate for child abuse, as the authors hypothesized that it would be more difficult for caregivers to forgo care than for non-life-threatening abuse. Mean monthly hospital admissions for AHT across…
Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study
In an international cohort study, pregnant women with COVID-19 (n=706) were at increased risk for preeclampsia/eclampsia, severe infections, ICU admissions, preterm birth, severe neonatal morbidity and severe perinatal morbidity and mortality compared to those without a COVID-19 diagnosis (n=1,424). Asymptomatic SARS-CoV-2 infection was only associated with increased risk for maternal morbidity and preeclampsia. 13% of…
High-Dimensional Characterization of Post-Acute Sequalae of COVID-19
COVID-19 patients who survived beyond the first 30 days of illness (n>73,000) had a 1.6-fold increased risk of death compared those who did not have COVID-19 and were not hospitalized (n>4.9 million), according to analysis of databases from the Department of Veterans Affairs. The cohort study also examined 6-month incident sequelae and found that COVID-19…
Preliminary Findings of MRNA Covid-19 Vaccine Safety in Pregnant Persons
Among women in the V-safe pregnancy registry who reported completing pregnancy after receiving COVID-19 mRNA vaccines (Pfizer-BioNTech or Moderna) from December to February 201 (n=827), adverse pregnancy and neonatal outcomes occurred in similar proportions as previously studies of pregnant women conducted before the COVID-19 pandemic. 14% resulted in pregnancy loss, 86% resulted in live birth…
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
The SARS-CoV-2 single-dose adenovirus vector vaccine Ad26.COV2.S (Johnson & Johnson) protected against moderate to severe-critical COVID-19 ≥14 days after administration with 66.9% efficacy (95% CI: 59-73.4%) in a randomized, double-blind placebo-controlled phase 3 trial. 116 cases occurred among those receiving the vaccine (n=19,691) vs 348 cases in the placebo group (n=19,691). Efficacy ≥28 days after…
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis
[Pre-print, not peer-reviewed] 89% of 186 dialysis patients developed anti-SARS-CoV-2 spike antibodies following two doses of mRNA vaccines (Pfizer-BioNTech and Moderna). Among patients without prior SARS-CoV-2 infection (n=148), the seropositivity rate was 86%. A majority (70%) of seropositive patients had maximum titers for anti-spike IgG antibodies at least 14 days after the second dose. No…
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
2 SARS-CoV-2 breakthrough infections (infection >= 14 days after the second vaccine dose) were detected in a cohort of 417 employees at the Rockefeller University in New York City. Clinical symptoms of COVID-19 developed 19 days after Patient 1 (51-year-old woman) received their second dose of the Moderna vaccine, and 36 days after Patient 2…
Effectiveness of the BNT162b2 Vaccine in Preventing COVID-19 in the Working Age Population – First Results from a Cohort Study in Southern Sweden
[Pre-print, not peer-reviewed] The Pfizer-BioNTech vaccine was 86% effective in preventing infection >7 days after the second dose in a cohort study (n=806,000) in Sweden from December 2020 to February 2021. Effectiveness was only 42% >14 days after a single dose. The vaccinated population largely consisted of healthcare workers. SARS-CoV-2 incidence among unvaccinated individuals with…
Airport Traveler Testing Program for SARS-CoV-2 — Alaska, June–November 2020
0.8% of passengers arriving to Alaska from June to November 14, 2020 tested positive for SARS-CoV-2 (951 of 126,000 tests). Passengers tested on arrival made up roughly a third of all air travelers arriving in Alaska during the study period, as other travelers opted to be tested within 72 hours before arrival or to self-quarantine…
Previous page Next page